

| Manufacturer Name | NDC | Name of Prescription Drug | A description of the marketing and pricing plans used in the launch of the new drug | Estimated volume of patients who may be prescribed drug | Breakthrough therapy designation? (Y/N) | Priority Review? (Y/N) | Date and price of acquisition if the drug was not developed by the manufacturer else N/A |
|-------------------|-------------|-------------------------------|---|---|---|------------------------|--|
| Chiesi USA | 10122018002 | Lamzede (velmanase alfa-tycv) | \$4,000.00 per vial. Marketing to targeted alpha-mannosidosis treaters and centers, as well as for disease awareness given its rare prevalence. | 22 | N | Y | N/A |